{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:41:29Z","timestamp":1792201289912,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.blre.2021.100810","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T18:16:10Z","timestamp":1614449770000},"page":"100810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap"],"prefix":"10.1016","volume":"49","author":[{"given":"Anthony P.","family":"Longhitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.blre.2021.100810_bb0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2021.100810_bb0010","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2021.100810_bb0015","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0020","first-page":"3","article-title":"Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system","volume":"1","author":"Hayden","year":"1994","journal-title":"Ther Immunol"},{"issue":"15","key":"10.1016\/j.blre.2021.100810_bb0025","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.blre.2021.100810_bb0030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1074-7613(01)00234-5","article-title":"The immunological synapse of CTL contains a secretory domain and membrane bridges","volume":"15","author":"Stinchcombe","year":"2001","journal-title":"Immunity."},{"issue":"5891","key":"10.1016\/j.blre.2021.100810_bb0035","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1016\/j.blre.2021.100810_bb0045","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood."},{"issue":"2 Pt A","key":"10.1016\/j.blre.2021.100810_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0055","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct Blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a Phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2021.100810_bb0065","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/eji.1830230924","article-title":"Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels","volume":"23","author":"Matthys","year":"1993","journal-title":"Eur J Immunol"},{"issue":"21","key":"10.1016\/j.blre.2021.100810_bb0070","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pcl.2012.03.002","article-title":"Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes","volume":"59","author":"Canna","year":"2012","journal-title":"Pediatr Clin N Am"},{"issue":"26","key":"10.1016\/j.blre.2021.100810_bb0085","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood."},{"issue":"26","key":"10.1016\/j.blre.2021.100810_bb0090","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2021.100810_bb0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for Sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100810_bb0105","series-title":"Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies","author":"Syed","year":"2019"},{"issue":"9","key":"10.1016\/j.blre.2021.100810_bb0110","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0115","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.blre.2021.100810_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of Chimeric Antigen Receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3\u20134","key":"10.1016\/j.blre.2021.100810_bb0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18632\/oncoscience.406","article-title":"Programming a serial killer: CAR T cells form non-classical immune synapses","volume":"5","author":"Davenport","year":"2018","journal-title":"Oncoscience."},{"key":"10.1016\/j.blre.2021.100810_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","article-title":"Development of CAR T cells designed to improve antitumor efficacy and safety","volume":"178","author":"Jaspers","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.blre.2021.100810_bb0135","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4161\/onci.20592","article-title":"A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)","volume":"1","author":"Stone","year":"2012","journal-title":"Oncoimmunology."},{"issue":"18","key":"10.1016\/j.blre.2021.100810_bb0140","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0145","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.blre.2021.100810_bb0150","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2021.100810_bb0165","series-title":"Interleukin 6 is not Made by Chimeric Antigen Receptor T Cells and does not Impact their Function","author":"Barrett","year":"2016"},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2021.100810_bb0175","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1136\/annrheumdis-2011-201087","article-title":"Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and\/or TNF inhibitors: a large, open-label study close to clinical practice","volume":"71","author":"Bykerk","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.blre.2021.100810_bb0180","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/s10165-010-0279-5","article-title":"Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions","volume":"20","author":"Nishimoto","year":"2010","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0185","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00040-08","article-title":"Infectious complications associated with monoclonal antibodies and related small molecules","volume":"22","author":"Salvana","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"issue":"6","key":"10.1016\/j.blre.2021.100810_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179179","article-title":"Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan","volume":"12","author":"Mori","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2021.100810_bb0200","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-cell-recruiting antibodies in B-cell malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0205","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2021.100810_bb0210","first-page":"1","article-title":"Changing epidemiology of bacterial infection in neutropenic patients with cancer","volume":"50","author":"Carratala","year":"2000","journal-title":"Antibiot Chemother"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0215","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/1874279301206010046","article-title":"Risk of infections in adult patients with haematological malignancies","volume":"6","author":"N\u00f8rgaard","year":"2012","journal-title":"Open Infect Dis J"},{"issue":"11","key":"10.1016\/j.blre.2021.100810_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002685","article-title":"Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study","volume":"15","author":"Warny","year":"2018","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.blre.2021.100810_bb0225","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1086\/596756","article-title":"HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines","volume":"48","author":"Brooks","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2021.100810_bb0230","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.blre.2021.100810_bb0235","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2249.2008.03851.x","article-title":"Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency","volume":"155","author":"Tarzi","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.blre.2021.100810_bb0245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/ACI.0b013e32835914b9","article-title":"The many faces of the clinical picture of common variable immune deficiency","volume":"12","author":"Resnick","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jmv.1890360113","article-title":"Immunoglobulin G subclasses and lymphocyte stimulatory responses to cytomegalovirus in transplant patients with primary cytomegalovirus infections","volume":"36","author":"Mathiesen","year":"1992","journal-title":"J Med Virol"},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0255","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.blre.2021.100810_bb0260","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3109\/10428194.2012.750723","article-title":"Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia","volume":"54","author":"Kontoyiannis","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2021.100810_bb0265","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1017\/S0950268814002131","article-title":"Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study","volume":"143","author":"Huaman","year":"2015","journal-title":"Epidemiol Infect"},{"issue":"13","key":"10.1016\/j.blre.2021.100810_bb0270","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","article-title":"Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia","volume":"2","author":"Stein","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2021.100810_bb0275","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","article-title":"Benefit\u2013risk assessment of blinatumomab in the treatment of relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Stein","year":"2019","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0280","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2017.1338270","article-title":"Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab","volume":"16","author":"Wilke","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"287","key":"10.1016\/j.blre.2021.100810_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2021.100810_bb0290","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.blre.2014.01.004","article-title":"Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection","volume":"28","author":"Teh","year":"2014","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0305","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0310","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3324\/haematol.2014.114025","article-title":"Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies","volume":"100","author":"Teh","year":"2015","journal-title":"Haematologica."},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0315","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/leu.2017.219","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2021.100810_bb0320","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.idc.2010.01.010","article-title":"Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology","volume":"24","author":"Wingard","year":"2010","journal-title":"Infect Dis Clin N Am"},{"issue":"8","key":"10.1016\/j.blre.2021.100810_bb0325","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.blre.2021.100810_bb0330","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.blre.2021.100810_bb0335","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE(R)) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology."},{"issue":"6","key":"10.1016\/j.blre.2021.100810_bb0340","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr Opin Biotechnol"},{"issue":"9","key":"10.1016\/j.blre.2021.100810_bb0345","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","article-title":"The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial","volume":"127","author":"Heiss","year":"2010","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.blre.2021.100810_bb0350","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","article-title":"Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer","volume":"119","author":"Knodler","year":"2018","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0355","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100810_bb0360","doi-asserted-by":"crossref","DOI":"10.1590\/1518-8345.1233.2787","article-title":"Evidence-based measures to prevent central line-associated bloodstream infections: a systematic review","volume":"24","author":"Perin","year":"2016","journal-title":"Rev Lat Am Enfermagem"},{"issue":"9","key":"10.1016\/j.blre.2021.100810_bb0365","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1093\/cid\/cir257","article-title":"Guidelines for the prevention of intravascular catheter-related infections","volume":"52","author":"O\u2019Grady","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2021.100810_bb0370","first-page":"147","article-title":"Current strategies for the prevention and management of central line-associated bloodstream infections","volume":"3","author":"Han","year":"2010","journal-title":"Infect Drug Resist"},{"issue":"8","key":"10.1016\/j.blre.2021.100810_bb0375","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100810_bb0380","first-page":"1","article-title":"CAR-T cell therapy and infection: a review","author":"Bupha-Intr","year":"2020","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"8","key":"10.1016\/j.blre.2021.100810_bb0385","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2021.100810_bb0390","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0395","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5694\/mja2.50160","article-title":"Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement","volume":"210","author":"Doyle","year":"2019","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.blre.2021.100810_bb0400","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.2012.09233.x","article-title":"Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients","volume":"159","author":"Minarik","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100810_bb0405","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fmicb.2019.01186","article-title":"Human Cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients","volume":"10","author":"Stern","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.blre.2021.100810_bb0410","series-title":"National Blood A","article-title":"A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks [electronic resource]: final report v04\/Biotext Science Information Consultants","author":"Biotext Science Information C","year":"2004"},{"issue":"3","key":"10.1016\/j.blre.2021.100810_bb0415","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.blre.2021.100810_bb0420","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib may impair serological responses to influenza vaccination","volume":"102","author":"Douglas","year":"2017","journal-title":"Haematologica."},{"issue":"35","key":"10.1016\/j.blre.2021.100810_bb0425","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100810_bb0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","article-title":"A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100810_bb0435","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2018-99-111529","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"132","author":"Westervelt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100810_bb0440","series-title":"Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart\u00ae Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients","author":"Godwin","year":"2019"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100810_bb0445","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-99-118344","article-title":"Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study","volume":"132","author":"Budde","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100810_bb0450","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2018-99-110207","article-title":"CD20-Tcb (RG6026), a Novel 2: 1 Format T-cell-engaging bispecific antibody, induces complete remissions in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma: preliminary results from a Phase I first in human trial","volume":"132","author":"Hutchings","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100810_bb0455","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2018-99-109769","volume":"132","author":"Topp","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2021.100810_bb0460","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2019-128528","article-title":"AMG 701 potently induces anti-multiple myeloma (MM) functions of t cells and IMiDs further enhance its efficacy to prevent MM relapse in vivo","volume":"134","author":"Cho","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.blre.2021.100810_bb0465","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8551","article-title":"GO39775: a multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5\/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma","volume":"38","author":"Cohen","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2021.100810_bb0470","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2019-121805","article-title":"Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a Phase I study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Raje","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100810_bb0475","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2018-99-112500","article-title":"REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to that of BCMA CAR T cells","volume":"132","author":"Dilillo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100810_bb0480","series-title":"Slides Presented at: 23rd Congress of EHA","article-title":"Preclinical evaluation of the new BCMAxCD3 bispecific antibody JNJ-957 for the treatment of multiple myeloma","year":"2018"},{"key":"10.1016\/j.blre.2021.100810_bb0485","series-title":"Pre-Clinical Development of TNB-383B, a Fully Human T-Cell Engaging Bispecific Antibody Targeting BCMA for the Treatment of Multiple Myeloma","author":"Buelow","year":"2018"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2021.100810_bb0490","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): interim results of a Phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.blre.2021.100810_bb0495","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3132","article-title":"Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed\/refractory multiple myeloma","volume":"36","author":"Richter","year":"2018","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2021.100810_bb0500","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:25:01Z","timestamp":1759436701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":100,"alternative-id":["S0268960X21000163"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100810","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100810"}}